Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001209191-21-054115)

Filing Details

Accession Number:
0001209191-21-054115
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-31 17:23:46
Reporting Period:
2021-08-27
Accepted Time:
2021-08-31 17:23:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1679082 Myovant Sciences Ltd. MYOV Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1714080 Camilo Juan Ferreira Arjona C/O Myovant Sciences Inc.
2000 Sierra Point Parkway, 9Th Floor
Brisbane CA 94005		 Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2021-08-27 1,978 $22.69 171,329 No 4 S Direct
Common Shares Acquisiton 2021-08-30 21,000 $7.78 192,329 No 4 M Direct
Common Shares Disposition 2021-08-30 21,000 $24.05 171,329 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2021-08-30 21,000 $0.00 21,000 $7.78
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
166,100 2027-08-14 No 4 M Direct
Footnotes
  1. Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
  2. Shares sold pursuant to a 10b5-1 trading plan.
  3. The shares were sold at prices ranging from $24.00 to $24.20. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.